Preclinical Development of CD38-Targeted [(89)Zr]Zr-DFO-Daratumumab for Imaging Multiple Myeloma

Multiple myeloma (MM) is a plasma B-cell hematologic cancer that causes significant skeletal morbidity. Despite improvements in survival, heterogeneity in response remains a major challenge in MM. Cluster of differentiation 38 (CD38) is a type II transmembrane glycoprotein overexpressed in myeloma c...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Nucl Med
Asıl Yazarlar: Ghai, Anchal, Maji, Dolonchampa, Cho, Nicholas, Chanswangphuwana, Chantiya, Rettig, Michael, Shen, Duanwen, DiPersio, John, Akers, Walter, Dehdashti, Farrokh, Achilefu, Samuel, Vij, Ravi, Shokeen, Monica
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Society of Nuclear Medicine 2018
Konular:
Oncology
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5807532/
https://ncbi.nlm.nih.gov/pubmed/29025987
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.117.196063
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller